• Home
  • Industry News
  • CytRx Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle

CytRx Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle


After updating data results from a Phase III trial evaluating aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas, California-based CytRx plans to seek regulatory approval sometime during 2017 for a drug once thought dead.
Source link